Pyxis Oncology’s IPO raised $168 million as the biotech steers toward the clinic with drug candidates and technology licensed from Pfizer. Theseus Pharma, IsoPlexis, and Cognition Therapeutics also went public; combined the four companies raised nearly half a billion dollars.
It has a patent-pending “biochip” technology that analyzes and “fingerprints” single cells, studying their immune response: That is, the excretion of a number of proteins like cytokines, chemokines and growth factors.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
IsoPlexis, a Yale spinout developing an immunologic assay that helps researchers understand how therapies impact individual patients on a cellular level, seems to have raised a nice chunk of startup capital. The company, formed last year by a couple of MBA candidates, has raised $1.3 million of a $1.7 million early-stage round, according to a […]